Advertisement

Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Advertisement

Advertisement




May
15
Today In Oncology
Does the Timing of Immunotherapy Administration Affect Outcomes in Advanced Cancers
Combination Enzalutamide and Radium-223 Extends Overall Survival in Bone-Dominant mCRPC
Sonrotoclax Receives Accelerated Approval in Relapsed or Refractory MCL
FDA Approves Combination Regimen for Newly Diagnosed AML
Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo